Compounds > 6-6-dimethyl-5-8-dihydropyrano[4-5]thieno[1-2-c]pyrimidin-4-amine

6-6-dimethyl-5-8-dihydropyrano[4-5]thieno[1-2-c]pyrimidin-4-amine and Neoplasm-Metastasis

6-6-dimethyl-5-8-dihydropyrano[4-5]thieno[1-2-c]pyrimidin-4-amine has been researched along with Neoplasm-Metastasis* in 1 studies

Other Studies

1 other study(ies) available for 6-6-dimethyl-5-8-dihydropyrano[4-5]thieno[1-2-c]pyrimidin-4-amine and Neoplasm-Metastasis

Article	Year
Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors. Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19 4-Aminobenzothieno[3,2-d]pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5,6-substituted 4-aminothieno[2,3-d]pyrimidines with low micromolar inhibition of LIMK1. Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Lim Kinases; Molecular Structure; Molecular Targeted Therapy; Molecular Weight; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Stereoisomerism; Structure-Activity Relationship	2011

Article

Year

Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.

Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19

4-Aminobenzothieno[3,2-d]pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5,6-substituted 4-aminothieno[2,3-d]pyrimidines with low micromolar inhibition of LIMK1.

Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Lim Kinases; Molecular Structure; Molecular Targeted Therapy; Molecular Weight; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011